文献速递泌尿男性生殖肿瘤

Decipher基因组分类器在前列腺切除术后高危男性中预测转移性疾病表现的个体患者水平Meta分析

Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.
PubMed 文献 · J Clin Oncol · 2017-03-30

该研究对5项研究(共975例患者,其中855例有个体患者水平数据)进行Meta分析,中位随访8年。Decipher分类为低、中、高危的患者10年累计转移发生率分别为5.5%、15.0%、26.7%(P<.001)。在多变量分析中,校正临床病理变量后,Decipher每0.1单位仍为转移的显著预测因子(HR 1.30;95%CI 1.14-1.47;P<.001)。结论认为Decipher可独立改善前列腺切除术后患者的预后判断。

要点

  • Decipher分类低、中、高危患者10年累计转移率分别为5.5%、15.0%、26.7%(P<.001)。
  • 汇总5项研究的Decipher HR为每0.1单位1.52(95%CI 1.39-1.67;I²=0%)。
  • 多变量分析中Decipher每0.1单位HR为1.30(95%CI 1.14-1.47;P<.001)。

核心结论

  • Decipher基因组分类器可独立改善前列腺切除术后患者的预后判断,并在几乎所有临床病理、人口学和治疗亚组中均如此。
  • 未来需研究如何最好地将基因组检测纳入临床决策和后续治疗推荐。

研究设计与样本

  • 对2011年至2016年发表的5项研究进行个体患者水平Meta分析,共975例患者,其中855例有个体患者水平数据,中位随访8年。
  • 检索MEDLINE、EMBASE和Decipher基因组资源信息数据库。
  • 采用多变量Cox比例风险模型拟合个体患者数据,并使用随机效应模型汇总研究特异性风险比(HR)进行Meta分析,采用I²检验确定研究间异质性程度。

主要发现

  • 在总队列中,Decipher分类为低、中、高危的患者分别占60.9%、22.6%和16.5%。
  • 低、中、高危三类的10年累计转移发生率分别为5.5%、15.0%和26.7%(P<.001)。
  • 汇总5项研究的Decipher HR为每0.1单位1.52(95%CI 1.39-1.67;I²=0%)。
  • 在个体患者数据的多变量分析中,校正临床病理变量后,Decipher每0.1单位仍为转移的统计学显著预测因子(HR 1.30;95%CI 1.14-1.47;P<.001)。
  • 仅临床模型预测10年远处转移的C指数为0.76,加入Decipher后增至0.81。

关键数值与推荐

  • Decipher分类低、中、高危的10年累计转移发生率分别为5.5%、15.0%和26.7%(P<.001)。
  • 汇总5项研究的Decipher HR为每0.1单位1.52(95%CI 1.39-1.67;I²=0%)。
  • 多变量分析中Decipher每0.1单位HR为1.30(95%CI 1.14-1.47;P<.001)。
  • 仅临床模型预测10年远处转移的C指数为0.76,加入Decipher后为0.81。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To perform the first meta-analysis of the performance of the genomic classifier test, Decipher, in men with prostate cancer postprostatectomy. Methods MEDLINE, EMBASE, and the Decipher genomic resource information database were searched for published reports between 2011 and 2016 of men treated by prostatectomy that assessed the benefit of the Decipher test. Multivariable Cox proportional hazards models fit to individual patient data were performed; meta-analyses were conducted by pooling the study-specific hazard ratios (HRs) using random-effects modeling. Extent of heterogeneity between studies was determined with the I2 test. Results Five studies (975 total patients, and 855 patients with individual patient-level data) were eligible for analysis, with a median follow-up of 8 years. Of the total cohort, 60.9%, 22.6%, and 16.5% of patients were classified by Decipher as low, intermediate, and high risk, respectively. The 10-year cumulative incidence metastases rates were 5.5%, 15.0%, and 26.7% ( P < .001), respectively, for the three risk classifications. Pooling the study-specific Decipher HRs across the five studies resulted in an HR of 1.52 (95% CI, 1.39 to 1.67; I2 = 0%) per 0.1 unit. In multivariable analysis of individual patient data, adjusting for clinicopathologic variables, Decipher remained a statistically significant predictor of metastasis (HR, 1.30; 95% CI, 1.14 to 1.47; P < .001) per 0.1 unit. The C-index for 10-year distant metastasis of the clinical model alone was 0.76; this increased to 0.81 with inclusion of Decipher. Conclusion The genomic classifier test, Decipher, can independently improve prognostication of patients postprostatectomy, as well as within nearly all clinicopathologic, demographic, and treatment subgroups. Future study of how to best incorporate genomic testing in clinical decision-making and subsequent treatment recommendations is warranted.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Spratt DE, Yousefi K, Deheshi S, et al. Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. J Clin Oncol. 2017. PMID: 28358655. doi:10.1200/JCO.2016.70.2811

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。